Seer

Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. Its Proteograph product suite comprises automation instrument and software, which provides workflow to make proteomic profiling. The company was founded by Philip Ma, Robert S. Langer Jr. and Omid C. Farokhzad on March 16, 2017 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Seer reports strong Q4 earnings, eyes revenue growth in 2023

Seer's Q4 2022 earnings reflect robust growth, driven by product sales and service projects. While challenges persist in China market access, the company is poised for revenue growth in 2023 through consumables and service contracts.

Seer (SEER) reports strong Q1 revenue growth and technology validation

Seer's Q1 performance showed revenue growth and a focus on disciplined expense management for financial strength.
The company's emphasis on Proteograph technology and customer validation positions it well for future growth.
While facing challenges in sales cycles and market opportunities, Seer is leveraging strategic initiatives for growth.

Seer reports revenue growth amidst challenges, focuses on strategic initiatives

Seer's Q2 performance showed revenue growth but faced a net loss due to operating expenses, prompting strategic cost management and sales cycle improvements.
Strengths lie in product expansion, strategic collaborations, and a focus on consumable margins, positioning Seer well in the proteomics market.
Challenges in adoption and cost alignment require focused efforts, while opportunities in customer engagement and strategic programs offer growth potential.

Seer reports Q3 revenue growth amidst macro challenges and partnerships

Seer's Q3 performance showed revenue growth but with a net loss, ending the quarter with a strong cash position. The company faces challenges from macroeconomic uncertainty impacting revenue and sales cycles. Seer's initiatives and partnerships present opportunities for growth and market adoption.

Seer reports revenue growth in 2023, eyes innovation for 2024

Seer's 2023 performance showed revenue growth and cost management improvements, ending the year well-funded.
Strong demand for technology and programs, coupled with a focus on innovation and evidence, positions Seer for growth.
Challenges in China and Europe markets require strategic navigation, while opportunities lie in revenue growth and technology advancements.

Seer reports Q1 revenue of $3.1M, focuses on innovation and cost-saving

Seer's Q1 2024 performance reflected revenue of $3.1 million, with cost-saving measures leading to reduced operating expenses. The company faces challenges in revenue growth due to slow platform adoption but is leveraging strengths in innovative technology and research support programs. Strategic initiatives like market share repurchase and global expansion present opportunities for future growth.

Seer reports revenue growth and strategic partnerships amid profitability challenges

Seer's Q3 performance reflects revenue growth and strategic collaborations despite financial losses.
The company's strong cash reserves and partnerships signal resilience and potential for market expansion.
While facing profitability challenges, Seer's innovative technology and market demand offer growth opportunities.
Navigating market uncertainties and optimizing financial performance are key focus areas for Seer.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 42nd Annual Health Care Conference in San Francisco, CA.

Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference

REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.

Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum

Seer technology receives recognition for excellence in the field of proteomics Seer technology receives recognition for excellence in the field of proteomics

Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500

Seer, Inc. (NASDAQ:SEER ) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Omid Farokhzad - President, CEO David Horn - CFO Conference Call Participants Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Marta Nazarovets - JP Morgan Operator Good day, and thank you for standing by. Welcome to the Seer Third Quarter 2023 Earnings Conference Call.

Seer, Inc. (SEER) Q3 2023 Earnings Call Transcript

Expanded access to the Proteograph™ Product Suite through the Seer Technology Access Center, new distributors and a new Center of Excellence Expanded access to the Proteograph™ Product Suite through the Seer Technology Access Center, new distributors and a new Center of Excellence

Seer Reports Third Quarter 2023 Financial Results

Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services

Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program

REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the third quarter of 2023 after market close on Tuesday, November 7, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Seer to Report Third Quarter 2023 Financial Results on November 7, 2023

American States Water

Beyond Meat

Embecta Corp

Farmers & Merchants Bancorp

iHeartMedia

SecureWorks Corp.

With the major equity indices printing some lackluster performances recently, the concept of contrarian stocks to buy might hit a bit differently now. Basically, with so many ideas printing red ink – and with analysts bashing that seemingly at every turn – a sudden reversal could yield tremendous profits.

7 Contrarian Stocks to Buy for the High-Stakes Gambler

REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences:

Seer to Participate in Upcoming September Investor Conferences

Seer CEO Omid Farokhzad said the company's sales are facing headwinds. The company lowered annual guidance for revenue.

Why Shares of Seer Are Slumping Wednesday

Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies

Seer Reports Second Quarter 2023 Financial Results

REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Canaccord Genuity 43rd Annual Growth Conference in Boston, MA.

Seer to Present at the Canaccord Genuity 43rd Annual Growth Conference

REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter of 2023 after market close on Tuesday, August 8, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Seer to Report Second Quarter 2023 Financial Results on August 8, 2023

Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific community to dig deeper into the proteome Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific community to dig deeper into the proteome

Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center

Seer's Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale Seer's Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale

Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies

Seer, Inc. (NASDAQ:SEER ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Omid Farokhzad - CEO, President and Chair David Horn - CFO Conference Call Participants Gabby Shaw - Morgan Stanley Kyle Boucher - TD Cowen Operator Good day. And thank you for standing by.

Seer, Inc. (SEER) Q1 2023 Earnings Call Transcript

Seer, Inc. (SEER) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.38 per share a year ago.

Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates

Grew revenue 22% year-over-year with continued growth in installed base and an increasing number of customer presentations and publications REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2023.

Seer Reports First Quarter 2023 Financial Results

REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Seer to Report First Quarter 2023 Financial Results on May 9, 2023

Peptide-level insights from deep, unbiased proteomics enable protein variant analysis of patient samples, revealing potential non-small cell lung cancer biomarkers Peptide-level insights from deep, unbiased proteomics enable protein variant analysis of patient samples, revealing potential non-small cell lung cancer biomarkers

Seer's Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression

Seer, Inc. (NASDAQ:SEER ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Carrie Mendivil – Investor Relations Omid Farokhzad – Chair, President and Chief Executive Officer David Horn – Chief Financial Officer Conference Call Participants Derik De Bruin – Bank of America Kyle Boucher – Cowen Tejas Savant – Morgan Stanley Operator Thank you for standing by and welcome to the Seer Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Seer, Inc. (SEER) Q4 2022 Earnings Call Transcript

Seer, Inc. (SEER) delivered earnings and revenue surprises of 14.29% and 0.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Seer, Inc. (SEER) Reports Q4 Loss, Misses Revenue Estimates

Grew revenue 134% and increased instruments shipped 129% year over year Grew revenue 134% and increased instruments shipped 129% year over year

Seer Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Outlook

Seer (SEER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

News for Seer Stock (SEER)